Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Quetiapine XR in Schizophrenic Patients

This study has been terminated.
(Planned number of 30 subjects could not be recruited during recruitment phase.)
Sponsor:
Collaborators:
Hannover Clinical Trial Center GmbH
AstraZeneca
Information provided by (Responsible Party):
Wolfgang Dillo, Hannover Medical School
ClinicalTrials.gov Identifier:
NCT01071135
First received: February 18, 2010
Last updated: November 10, 2011
Last verified: August 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: August 2010
  Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)